This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Enkephalin
From Proteopedia
| Line 1: | Line 1: | ||
| - | <StructureSection load=' | + | <StructureSection load='5E3A' size='400' side='right' caption='Structure of human DPP3 in complex with opioid peptide leu-enkephalin' scene=''> |
== General function == | == General function == | ||
'''Enkephalins''' were the first reported evidence of endogenous opioids in the brain, by John Hughes and Hans Kosterlitz in 1975 <ref>John Hughes, Terry Smith, Barry Morgan, Linda Fothergill, Purification and properties of enkephalin — The possible endogenous ligand for the morphine receptor, Life Sciences, | '''Enkephalins''' were the first reported evidence of endogenous opioids in the brain, by John Hughes and Hans Kosterlitz in 1975 <ref>John Hughes, Terry Smith, Barry Morgan, Linda Fothergill, Purification and properties of enkephalin — The possible endogenous ligand for the morphine receptor, Life Sciences, | ||
Revision as of 19:12, 29 November 2021
General functionEnkephalins were the first reported evidence of endogenous opioids in the brain, by John Hughes and Hans Kosterlitz in 1975 [1] [2]. They are pentapeptides that can be divided into two groups based on their carboxy-terminal amino acids: methionine-enkephalin and leucine-enkephalin. Enkephalin acts as a neurotransmitter through opioid receptors, more specifically through the [3]. The main functions of enkephalins include analgesia, but they are also involved in the control of respiratory, cardiovascular and gastrointestinal functions, and participate in neuroendocrine regulation [4] [5] [6]. Enkephalin is generated from the cleavage of the precursor pro-enkephalin, resulting in Met-enkephalin or Leu-enkephalin. The processing of one molecule of pro-enkephalin generates six copies of Met-enkephalin and one copy of Leu-enkephalin [3]. Enkephalin is mainly distributed throughout the central, peripheral and autonomic nervous system in mammals [3]. However, opioid receptors are broadly distributed in the body, such as the cardiac and gastrointestinal systems. StructureThe main conformations of enkephalin found in crystals have been classified in three categories, described as “extended,” “single bend,” and “double bend.”[7]. The picture below represents molecular models of Leu-enkephalin in the three main conformations found in solid state determinations when the peptide is dissolved in a DMSO/water cryomixture at 275 K. [8]. Physiological functionsAnalgesiaEnkephalins belong to one of the four major families of endogenous opioid ligands [9]. Opioid receptors couple to inhibitory G proteins and when they are activated Gα and Gβγ subunits dissociate and induce a signaling cascade that leads to a reduced neurotransmitter release [9]. All four opioid receptors inhibit N-, P/Q- and L-type voltage-gated calcium channels [9] [10] by the Gβγ subunit, which inhibits the entry of calcium to the pre-synaptic neuron, preventing the fusion of calcium-dependent synaptic vesicules with the membrane terminal and therefore blocking the neurotransmitter release. Transmission of pain signals is thus blocked. Enkephalins can be released from infiltrating immune cells at the site of injuries and from neurons in the central nervous system [9]. Stress response regulationSeveral studies showed the importance of enkephalins in anxiety and stress. A polymorphism in the gene encoding neutral endopeptidase involved in enkephalin metabolism, was identified in patients with anxiety disorders [11] [12]. Moreover, an enkephalin KO mice model had increased anxiety with the elevated plus maze (EPM), open field (OF) and light-dark box (LDB) tests, as well as an exaggerated startle response (SR), which is an unconscious defensive response to unexpected or threatened stimuli, and a reduced duration in the social interaction test (SI) [11] [13] [14] [15]. This suggests that a reduced enkephalin neurotransmission relates with the expression of anxiety. However, in other studies it appears that enkephalins enhanced the reactivity to chronic stress, as enkephalin KO mice were resistant to anxiety and depression-like behaviors after a chronic mild unpredictable stress [11] [16]. It seems that enkephalins have different effects on anxiety and stress and this might depend on the central nervous system region. In response to stress, Corticotropin-Releasing Factor (CRF) is released and stimulates the production of endogenous opioids such as endorphins and enkephalins. Enkephalin has been found to modulate the release of CRF from the paraventricular nucleus of the hypothalamus [3]. More knowledge on enkephalin pathways and their role is needed in order to fully understand stress regulation and a variety of stress- and anxiety- related disorders. Formation of social memoryEnkephalin has a depressant or inhibitory function of neuronal communication, and it is produced by VIP neurons [17], located in a small area of the hippocampus called CA2, which is known to be involved in the formation of social memory [18]. In mice, it is observed that VIP neurons show greater activity during the encounter with an unknown individual than against another relative and also when faced with a new object [19]. With the release of enkephalin by VIP interneurons in CA2, a special type of plasticity is induced, called ITDP (Input-timing-dependent plasticity), which is essential for the formation of social memory [20]. PathophysiologyDue to the wide distribution of the endogenous opioid system in the human body, its dysregulation has a high number of implications. One example of pain dysregulation is fibromyalgia, which is a widespread pain in the absence of identifiable peripheral pathology [21]. It appears that the endogenous opioid system is involved in some aspects of pain in fibromyalgia [22]. The concentration of endogenous opioids in the cerebrospinal fluid (CSF) of patients with fibromyalgia seems to be higher, which leads to a decreased availability and affinity of Mu-opioid receptors (MOR) [22]. This translates into an increase in pain neurotransmission. The enkephalin signaling pathway regulates various neural functions and can be altered by neurodegenerative disorders. In Alzheimer's disease (AD), elevated enkephalin levels may reflect compensatory processes or contribute to cognitive impairments.. The therapeutic potential of reducing enkephalin production or signaling merits further exploration.[23]. Decreased plasma met-enkephalin levels are vasogenic mediators in Systemic Sclerosis (SSc), and will associate with clinical manifestations of SSc-related vascular and fibrogenic injuries[24]. Clinical relevanceMet-Enkephalin (MENK) may contribute to immune responses against tumors and viral infections by activating multiple types of immune cells, enabling them to secrete various cytokines or directly kill target cells. The nuclear membrane of certain cancer cells expressed receptors to which MENK bound, resulting in marked growth inhibition of cancer cells in vitro[25]. Activation of δ opioid receptors acts against oxidative stress in the central nervous system and promotes neuron survival. It is able to cross the blood-brain barrier; it has been hypothesized to be a promising strategy to promote neuron regeneration, especially in brain damage caused by stroke [26]. The main and most known effect of enkephalins is analgesia, which makes the therapeutic use of enkephalins to treat pain one their main clinical relevant aspect. However, enkephalins have a relatively low stability in-vivo, due to their degradation by endogenous peptidases [3]. Two approaches have been proposed to this issue: the first one is the chemical modification of enkephalins while preserving their analgesic efficacy. One example of this is the design of D-Ala-methionine-enkephalin in 1976 by Pert et al. [27]. Kropotova et al. in 2020 have designed different modified enkephalins that are less accessible to endopeptidases [28]. The second approach to increase enkephalin stability in-vivo is the blocking of the peptidases themselves, such as enkephalinase and aminopeptidase. One example is DENKIs [3]. Dual Enkephalinase Inhibitors (DENKIs) are a novel therapeutic approach for opioid use disorders. This class of compounds physiologically activates the endogenous opioid system by inhibiting the enzymes responsible for the breakdown of enkephalins, protecting endogenous enkephalins, increasing their half-lives and physiological actions [29]. References
| ||||||||||||
Proteopedia Page Contributors and Editors (what is this?)
Borja Fernández García, Marina González Castilla, Michal Harel
